Catalog No.
DHG17629
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
Fusion - [SIRPα (SIRPA, CD172a, SHPS-1]2 - IGHG1 Fc (Fragment constant)
Clonality
Monoclonal
Target
Leukocyte surface antigen CD47, CD47, Antigenic surface determinant protein OA3, IAP, Integrin-associated protein, Protein MER6, MER6
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q08722
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
TTI-621, TTI 621, TTI621
Clone ID
TTI-621
A collagen-binding SIRPαFc fusion protein for targeted cancer immunotherapy., PMID:37722258
Blockade of the Immune Checkpoint CD47 by TTI-621 Potentiates the Response to Anti-PD-L1 in Cutaneous T-Cell Lymphoma., PMID:36863449
A SIRPαFc Fusion Protein Conjugated With the Collagen-Binding Domain for Targeted Immunotherapy of Non-Small Cell Lung Cancer., PMID:35422796
Emerging drugs for the treatment of cutaneous T-cell lymphoma., PMID:35235473
Inhibition of the CD47-SIRPα axis by TTI-621 to treat relapsed or refractory mycosis fungoides or Sézary syndrome., PMID:34627594
Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study., PMID:34627593
Current status of intralesional agents in treatment of malignant melanoma., PMID:34277838
Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies., PMID:33451977
Just eat it: A review of CD47 and SIRP-α antagonism., PMID:32517874
SIRPαFc treatment targets human acute myeloid leukemia stem cells., PMID:32054659
CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity., PMID:31852716
Antibody-Directed Therapies: Toward a Durable and Tolerable Treatment Platform for CTCL., PMID:31417860
Targeting CD47 in Sézary syndrome with SIRPαFc., PMID:30962222
Targeting CD47 as a cancer therapeutic strategy: the cutaneous T-cell lymphoma experience., PMID:29994903
Blocking "don't eat me" signal of CD47-SIRPα in hematological malignancies, an in-depth review., PMID:29709247
TTI-621 (SIRPαFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets., PMID:29084248
TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding., PMID:27856600
For research use only. Not for human or drug use.
